NMR-based metabolomics of urine in a mouse model of Alzheimer's disease: Identification of oxidative stress biomarkers

Journal of Clinical Biochemistry and Nutrition

Volumn 52, Issue 2, 2013, Pages 133-138

  Fukuhara, Kiyoshi ^a   Ohno, Akiko ^a   Ota, Yosuke ^a   Senoo, Yuya ^a   Maekawa, Keiko ^a   Okuda, Haruhiro ^a   Kurihara, Masaaki ^a   Okuno, Alato ^b   Niida, Shumpei ^b   Saito, Yoshiro ^a   Takikawa, Osamu ^b  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Alzheimer's disease; Biomarker; Metabolomics; NMR; Oxidative stress

Indexed keywords

3 HYDROXYKYNURENINE; ALLANTOIN; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; HOMOGENTISIC ACID; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; METABOLOMICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTON NUCLEAR MAGNETIC RESONANCE; URINE;

EID: 84875887643     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.12-118     Document Type: Article

References (34)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011; 377: 1019-1031.
2. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nature reviews Neuroscience 2007; 8: 499-509.
3. Amieva H, Le Goff M, Millet X, et aL Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008; 64: 492-498.
4. Bollard ME, Stanley EG, Lindon JC, Nicholson JK, Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed 2005; 18: 143-162. (Pubitemid 40716122)
5. Serkova NJ, Spratlin JL, Eckhardt SG. NMR-based metabolomics: translational application and treatment of cancer. Curr Opin Mol Ther 2007; 9: 572-585. (Pubitemid 350179097)
6. De Meyer T, Sinnaeve D, Van Gasse B, et el. NMR-based characterization of metabolic alterations in hypertension using an adaptive, intelligent binning algorithm. Anal Chem 2008; 80: 3783-3790. (Pubitemid 351705882)
7. Fukuhara K, Ohno A, Ando Y, Yamoto T, Okuda H. A 1H NMR-based metabolomics approach for mechanistic insight into acetaminophen-induced hepatotoxicity. Drug Metab Pharmacokinet 2011; 26: 399-406.
8. Lindon JC, Holmes E, Nicholson JK. Metabonomics in pharmaceutical R&D.FEBS J 2007, 274: 1140-1151.
9. Maher AD, Lindon JC, Nicholson JK. 1H NMR-based metabonomics for investigating diabetes. Future Med Chem 2009; 1: 737-747.
10. O'Connell TM. Recent advances in metabolomics in oncology. Bioanalysis 2012; 4: 431-451.
11. Powers R. NMR metabolomics and drug discovery. Magn Resort Chem 2009; 47 (Suppl 1): S2-S11.
12. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-1491. (Pubitemid 32801551)
13. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 2009; 204:309-314.
14. Martin JP Jr., Batkoff B. Homogentisic acid autoxidation and oxygen radical generation: implications for the etiology of alkaptonuric arthritis. Free Radic Biol Med 1987; 3: 241-250.
15. Il'yasova D, Scarbrough P, Spasojevic I. Urinary biomarkers of oxidative stams. Clin Chim Acta 2012; 413: 1446-1453.
16. Zeisel SH, daCostaKA, YoussefM, Hensey S. Conversion of dietary choline to trimethylamine and dimethylamine in rats: dose-response relationship. J Nutr 1989 119: 800-804. (Pubitemid 19164470)
17. Verri M, Pastoris O, Dossena M, et al. Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease. Int J Immunopathol Pharmacol 2012; 25: 345-353.
18. von Bemhardi R, Eugenin J. Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxid Redox Signal 2012; 16: 974-1031.
19. Bonda DJ, Mailankot M, Stone JG, et al. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep 2010; 15: 161-168.
20. Takikawa 0. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys Res Commun 2005; 338: 12-19. (Pubitemid 41540531)
21. Okuda S, Nishiyama N, Saito H, Katsuki H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc Natl Acad Sci USA 1996; 93: 12553-12558. (Pubitemid 26367182)
22. Femández-Cañón JM, Granadino B, Beltrán-Valero de Bernabé D, et al. The molecular basis of alkaptonuria. Nat Genet 1996; 14: 19-24.
23. Braconi D, Bianchini C, Bernardini G, et al. Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis. J Inherit Metab Dis 2011; 34: 1163-1176.
24. Serkova N, Fuller TF, Klawitter J, Preise CE, Niemann CU. H-NMR-based metabolic signatures of mild and severe ischemia/reperfiision injury in rat kidney transplants. Kidney Int 2005; 67: 1142-1151. (Pubitemid 41623341)
25. Leo GC, Darrow AL. NMR-based metabolomics of urine for the atherosclerotic mouse model using apolipoprotein-E deficient mice. Magn Reson Chem 2009; 47 (Suppl 1): S20-S25.
26. Benzie IF, Chung WY, Tomlinson B. Simultaneous measurement of allantoin and urate in plasma: analytical evaluation and potential clinical application in oxidant:antioxidant balance studies. Clin Chem 1999; 45: 901-904. (Pubitemid 29266623)
27. Moreira PI, Duarte Al, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 2009; 16: 741-761.
28. Honda K, Smith MA, Zhu X, et at. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 2005; 280: 20978-20986. (Pubitemid 40805655)
29. Moreira PI, Harris PL, Zhu X, et al. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts, J Alzheimers Dis 2007; 12: 195-206. (Pubitemid 47509369)
30. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 759-767. (Pubitemid 32678256)
31. Sultana R, Butterfield DA. Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 2010; 19: 341-353.
32. Rahmadi A, Steiner N, Münch G. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease. Clin Chem Lab Med 2011; 49: 385-391.
33. Butterfield DA, Bader Lange ML, Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta 2010; 1801: 924-929.
34. Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adh Migr 2009; 3: 88-93.